 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug AMBISOME: DO-NOT-KNOW[0m

[34mI attempted to consult FDAHandler to determine whether AMBISOME increases or decreases the risk of angioedema. However, despite multiple attempts, I did not receive any response from FDAHandler. [0m
[34mTherefore, I cannot provide a reliable answer based on FDA label data.[0m
[1;34m2[0m[34m. Drug AMPHOTERICIN B: The FDA label for AMPHOTERICIN B does not specifically mention angioedema as a risk associated with its use. However, there is a less than [0m[1;34m0.1[0m[34m% incidence rate of anaphylaxis, [0m
[34mwhich can include symptoms such as angioedema, associated with the use of ABELCET, a formulation of amphotericin B. Therefore, while angioedema is not explicitly listed, it may occur as part of an [0m
[34manaphylactic reaction to the drug, albeit rarely.[0m
[1;34m3[0m[34m. Drug ABELCET: ABELCET could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, but the available information does not quantify this risk beyond stating that [0m
[34manaphylaxis has been reported with an incidence rate of <[0m[1;34m0.1[0m[34m%. Therefore, while angioedema could occur, the degree of risk is not clearly defined.[0m
[34m                ---------[0m
[34m                Does the amphotericin b category of drugs increase the risk of[0m
[34m                angioedema, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema."[0m[32m,[0m
[32m      [0m[32m"Passage 2 states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than 0.1% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[32mABELCET formulation."[0m[32m,[0m
[32m      [0m[32m"Passage 3 mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <0.1%[0m
[32mfor anaphylaxis."[0m[32m,[0m
[32m      [0m[32m"Based on the information provided, it can be inferred that there is a potential for amphotericin B category drugs to increase the risk of angioedema, but this risk is very low [0m[32m([0m[32mless than 0.1%[0m[32m)[0m[32m [0m
[32mand not well quantified."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The amphotericin b category of drugs may increase the risk of angioedema, but the effect is rare and not well quantified."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema."[0m[34m,[0m
[34m      [0m[34m"Passage 2 states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than 0.1% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[34mABELCET formulation."[0m[34m,[0m
[34m      [0m[34m"Passage 3 mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <0.1%[0m
[34mfor anaphylaxis."[0m[34m,[0m
[34m      [0m[34m"Based on the information provided, it can be inferred that there is a potential for amphotericin B category drugs to increase the risk of angioedema, but this risk is very low [0m[34m([0m[34mless than 0.1%[0m[34m)[0m[34m [0m
[34mand not well quantified."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The amphotericin b category of drugs may increase the risk of angioedema, but the effect is rare and not well quantified."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than [0m[1;31m0.1[0m[31m% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[31mABELCET formulation.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <[0m[1;31m0.1[0m[31m% for[0m
[31manaphylaxis.[0m
[1;31m4[0m[31m. Based on the information provided, it can be inferred that there is a potential for amphotericin B category drugs to increase the risk of angioedema, but this risk is very low [0m[1;31m([0m[31mless than [0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m and [0m
[31mnot well quantified.[0m
[31m        -----[0m
[31m        Final answer: The amphotericin b category of drugs may increase the risk of angioedema, but the effect is rare and not well quantified.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is flawed because it conflates the incidence of anaphylaxis with the risk of angioedema. While anaphylaxis can include angioedema, the presence of anaphylaxis [0m
[32mdoes not necessarily indicate the presence of angioedema. The passages provided do not establish a direct link between amphotericin B drugs and angioedema, only a potential association with [0m
[32manaphylaxis, which is a broader category of allergic reaction. Therefore, the conclusion that amphotericin B drugs may increase the risk of angioedema is not supported by the evidence provided. The [0m
[32mcorrect conclusion should be that there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs based on the information provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is flawed because it conflates the incidence of anaphylaxis with the risk of angioedema. While anaphylaxis can include angioedema, the presence of anaphylaxis [0m
[34mdoes not necessarily indicate the presence of angioedema. The passages provided do not establish a direct link between amphotericin B drugs and angioedema, only a potential association with [0m
[34manaphylaxis, which is a broader category of allergic reaction. Therefore, the conclusion that amphotericin B drugs may increase the risk of angioedema is not supported by the evidence provided. The [0m
[34mcorrect conclusion should be that there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs based on the information provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is flawed because it conflates the incidence of anaphylaxis with the risk of angioedema. While anaphylaxis can include angioedema, the presence of anaphylaxis [0m
[31mdoes not necessarily indicate the presence of angioedema. The passages provided do not establish a direct link between amphotericin B drugs and angioedema, only a potential association with [0m
[31manaphylaxis, which is a broader category of allergic reaction. Therefore, the conclusion that amphotericin B drugs may increase the risk of angioedema is not supported by the evidence provided. The [0m
[31mcorrect conclusion should be that there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs based on the information provided.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Passage 1 indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema."[0m[32m,[0m
[32m      [0m[32m"Passage 2 states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than 0.1% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[32mABELCET formulation."[0m[32m,[0m
[32m      [0m[32m"Passage 3 mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <0.1%[0m
[32mfor anaphylaxis."[0m[32m,[0m
[32m      [0m[32m"The evidence does not establish a direct link between amphotericin B drugs and angioedema, only a potential association with anaphylaxis, which is a broader category of allergic reaction."[0m[32m,[0m
[32m      [0m[32m"Therefore, based on the information provided, there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the amphotericin b category of drugs on the risk of angioedema based on the information provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"Passage 1 indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema."[0m[34m,[0m
[34m      [0m[34m"Passage 2 states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than 0.1% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[34mABELCET formulation."[0m[34m,[0m
[34m      [0m[34m"Passage 3 mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <0.1%[0m
[34mfor anaphylaxis."[0m[34m,[0m
[34m      [0m[34m"The evidence does not establish a direct link between amphotericin B drugs and angioedema, only a potential association with anaphylaxis, which is a broader category of allergic reaction."[0m[34m,[0m
[34m      [0m[34m"Therefore, based on the information provided, there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the amphotericin b category of drugs on the risk of angioedema based on the information provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the amphotericin b category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. Passage [0m[1;31m1[0m[31m indicates that there is no available information from the FDA label for AMBISOME regarding its association with angioedema.[0m
[1;31m2[0m[31m. Passage [0m[1;31m2[0m[31m states that the FDA label for AMPHOTERICIN B does not specifically mention angioedema, but notes a less than [0m[1;31m0.1[0m[31m% incidence rate of anaphylaxis, which can include angioedema, for the [0m
[31mABELCET formulation.[0m
[1;31m3[0m[31m. Passage [0m[1;31m3[0m[31m mentions that ABELCET, a formulation of amphotericin B, could potentially be associated with angioedema as part of an allergic reaction or anaphylaxis, with an incidence rate of <[0m[1;31m0.1[0m[31m% for[0m
[31manaphylaxis.[0m
[1;31m4[0m[31m. The evidence does not establish a direct link between amphotericin B drugs and angioedema, only a potential association with anaphylaxis, which is a broader category of allergic reaction.[0m
[1;31m5[0m[31m. Therefore, based on the information provided, there is no clear evidence of an effect on the risk of angioedema from the amphotericin B category of drugs.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the amphotericin b category of drugs on the risk of angioedema based on the information provided.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.8[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.001[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The available information from the FDA label for AMPHOTERICIN B and its formulation ABELCET does not specifically mention angioedema as a risk. While there is a mention of [0m
[32manaphylaxis, which can include angioedema, the incidence rate is less than 0.1%, and there is no direct evidence linking amphotericin B drugs to an increased risk of angioedema. Therefore, there is no[0m
[32mclear effect established."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-amphotericin b[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
